Exclusive Platform Rights Eos Biosciences holds worldwide exclusive rights to a novel drug-targeting and drug-delivery platform called Eosomes, developed at Cedars-Sinai Medical Center. This enables potential licensing and collaboration deals with pharma or biotech partners seeking targeted therapies.

Broad Therapeutic Reach The Eosomes platform can entrap and deliver therapeutics to disease sites and is adaptable to a wide range of diseases and therapeutic modalities, creating multiple partnership paths across oncology, autoimmune, CNS, and more.

Lean Collaboration Model With a small team and early stage status, the company is well positioned for strategic collaborations, out-licensing, and milestone driven partnerships with larger companies to scale development and commercialization.

Compelling Value Proposition The platform’s targeted delivery is designed to improve efficacy and safety of payloads, offering a strong value proposition for partners seeking asset enhancement or next generation formulations.

Strategic Outreach Global exclusivity combined with a differentiated delivery mechanism makes Eos a candidate for proactive engagement by mid sized and large biotech and pharmaceutical firms looking to expand their pipelines with innovative delivery solutions.